相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
Christian M. Gill et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)
PorinPredict: In Silico Identification of OprD Loss from WGS Data for Improved Genotype-Phenotype Predictions of P. aeruginosa Carbapenem Resistance
Michael Biggel et al.
MICROBIOLOGY SPECTRUM (2023)
Horizontal Gene Transfer of Antibiotic Resistance Genes in Biofilms
Claudia Michaelis et al.
ANTIBIOTICS-BASEL (2023)
Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
Andrea Marino et al.
ANTIBIOTICS-BASEL (2023)
Worldwide Dissemination of blaKPC Gene by Novel Mobilization Platforms in Pseudomonas aeruginosa: A Systematic Review
Daniela Forero-Hurtado et al.
Antibiotics-Basel (2023)
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
Jinnethe Reyes et al.
LANCET MICROBE (2023)
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019)
Miki Takemura et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)
Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa
Thilo Kohler et al.
NATURE COMMUNICATIONS (2023)
Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
Andrea Marino et al.
ANTIBIOTICS-BASEL (2023)
Multi-drug resistant Pseudomonas aeruginosa: a 2019-2020 single center retrospective case control study
Ann Fan Yang et al.
INFECTION PREVENTION IN PRACTICE (2023)
In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales
Juan Carlos Vazquez-Ucha et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies
Jean-Francois Timsit et al.
CLINICAL INFECTIOUS DISEASES (2022)
Occurrence of plasmid-mediated quinolone resistance genes in Pseudomonas aeruginosa strains isolated from clinical specimens in southwest Iran: a multicentral study
Morteza Saki et al.
SCIENTIFIC REPORTS (2022)
Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis
Laura J. Sherrard et al.
JOURNAL OF CYSTIC FIBROSIS (2022)
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Ashlan J. Kunz Coyne et al.
INFECTIOUS DISEASES AND THERAPY (2022)
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2022)
Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)
Alba Bergas et al.
MICROBIOLOGY SPECTRUM (2022)
New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review
Angela Raffaella Losito et al.
ANTIBIOTICS-BASEL (2022)
Role of Efflux Pumps on Antimicrobial Resistance in Pseudomonas aeruginosa
Andre Bittencourt Lorusso et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa
Cristina Lasarte-Monterrubio et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)
What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?
Sebastien Reig et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Mechanism of action of cefiderocol
Alex Soriano et al.
REVISTA ESPANOLA DE QUIMIOTERAPIA (2022)
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem
Marin H. Kollef et al.
CRITICAL CARE (2022)
High prevalence of blaVEB, blaGES and blaPER genes in beta-lactam resistant clinical isolates of Pseudomonas aeruginosa
Saboura Haghighi et al.
AIMS MICROBIOLOGY (2022)
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
Ivan Titov et al.
CLINICAL INFECTIOUS DISEASES (2021)
Expression of the MexXY Aminoglycoside Efflux Pump and Presence of an Aminoglycoside-Modifying Enzyme in Clinical Pseudomonas aeruginosa Isolates Are Highly Correlated
Alexander Seupt et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Structural basis for plazomicin antibiotic action and resistance
Tolou Golkar et al.
COMMUNICATIONS BIOLOGY (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
Reassessment of the cooperativity between efflux system MexAB-OprM and cephalosporinase AmpC in the resistance of Pseudomonas aeruginosa to β-lactams
Melanie Grosjean et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
An update on cefepime and its future role in combination with novel beta-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa
Burcu Isler et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Ceftolozane-tazobactam: When, how and why using it?
Inmaculada Lopez Montesinos et al.
REVISTA ESPANOLA DE QUIMIOTERAPIA (2021)
Mobile Carbapenemase Genes in Pseudomonas aeruginosa
Eun-Jeong Yoon et al.
FRONTIERS IN MICROBIOLOGY (2021)
Pseudomonas aeruginosa Resistance to Bacteriophages and Its Prevention by Strategic Therapeutic Cocktail Formulation
Andrew Vaitekenas et al.
ANTIBIOTICS-BASEL (2021)
β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
Karl A. Glen et al.
PATHOGENS (2021)
Expression of RND efflux pumps mediated antibiotic resistance in Pseudomonas aeruginosa clinical strains
Abed Zahedi Bialvaei et al.
MICROBIAL PATHOGENESIS (2021)
Quorum Sensing Inhibitors to Quench P. aeruginosa Pathogenicity
Marine Duplantier et al.
PHARMACEUTICALS (2021)
The Building Blocks of Antimicrobial Resistance in Pseudomonas aeruginosa: Implications for Current Resistance-Breaking Therapies
R. Fredi Langendonk et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)
Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
Patricia J. Simner et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
George L. Daikos et al.
ANTIBIOTICS-BASEL (2021)
Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program
John E. Mazuski et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2020)
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch et al.
CLINICAL INFECTIOUS DISEASES (2020)
Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia
Owen R. Albin et al.
CLINICAL INFECTIOUS DISEASES (2020)
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
Matteo Bassetti et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Distribution of Class B and Class A β-Lactamases in Clinical Strains of Pseudomonas aeruginosa: Comparison of Phenotypic Methods and High-Resolution Melting Analysis (HRMA) Assay
Sanaz Dehbashi et al.
INFECTION AND DRUG RESISTANCE (2020)
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update
Ester del Barrio-Tofino et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of Pseudomonas aeruginosa Isolates
Christian M. Gill et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Pseudomonas aeruginosa Biofilms
Minh Tam Tran Thi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
GPC-1, a novel class A carbapenemase detected in a clinical Pseudomonas aeruginosa isolate
Jennifer Schauer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
Janet Y. Wu et al.
INFECTIOUS DISEASES AND THERAPY (2020)
New beta-Lactam-beta-Lactamase Inhibitor Combinations
Dafna Yahav et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2019)
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections
Khalid Eljaaly et al.
DRUGS (2019)
OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
Christopher Frohlich et al.
MSPHERE (2019)
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa
Jose-Manuel Ortiz de la Rosa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Catherine L. Tooke et al.
JOURNAL OF MOLECULAR BIOLOGY (2019)
Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa
Sandra Mikhail et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Role of outer membrane permeability, efflux mechanism, and carbapenemases in carbapenem-nonsusceptible Pseudomonas aeruginosa from Dubai hospitals: Results of the first cross-sectional survey
Carole Ayoub Moubareck et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Re: Once-Daily Plazomicin for Complicated Urinary Tract Infections
Edward M. Schaeffer
JOURNAL OF UROLOGY (2019)
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
Juan P. Horcajada et al.
CLINICAL MICROBIOLOGY REVIEWS (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
Molecular mechanisms of polymyxin resistance and detection of mcr genes
Patrik Mlynarcik et al.
BIOMEDICAL PAPERS-OLOMOUC (2019)
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Zheng Pang et al.
BIOTECHNOLOGY ADVANCES (2019)
Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
George H. Talbot et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections
Nicole Gidaya Bonine et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2019)
Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae
M. Thwaites et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
β-lactam resistance: The role of low molecular weight penicillin binding proteins, β-lactamases and LD-transpeptidases in bacteria associated with respiratory tract infections
Christopher S. Ealand et al.
IUBMB LIFE (2018)
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
Gregory G. Stone et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
KPC-2 carbapenemase-producing Pseudomonas aeruginosa reaching Germany
Juergen Benjamin Hagemann et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Pacing across the membrane: the novel PACE family of efflux pumps is widespread in Gram-negative pathogens
Karl A. Hassan et al.
RESEARCH IN MICROBIOLOGY (2018)
Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis
Han Zhong et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Oxygen Limitation Enhances the Antimicrobial Activity of Fosfomycin in Pseudomonas aeruginosa Following Overexpression of glpT Which Encodes Glycerol-3-Phosphate/Fosfomycin Symporter
Hidetada Hirakawa et al.
FRONTIERS IN MICROBIOLOGY (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa
Gertrudis Horna et al.
SCIENTIFIC REPORTS (2018)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
Jason C. Gallagher et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Extended-Spectrum Beta-lactamase Producers: Detection for the Diagnostic Laboratory
Rani Diana Sahni et al.
JOURNAL OF GLOBAL INFECTIOUS DISEASES (2018)
In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
Akinobu Ito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
Antoni Torres et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Contamination of hospital tap water: the survival and persistence of Pseudomonas aeruginosa on conventional and 'antimicrobial' outlet fittings
C. F. Hutchins et al.
JOURNAL OF HOSPITAL INFECTION (2017)
Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence
M. Fata Moradali et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2017)
Pseudomonas aeruginosa Ventilator-Associated Pneumonia Induces Lung Injury through TNF-α/c-Jun NH2-Terminal Kinase Pathways
Ying-Wei Yang et al.
PLOS ONE (2017)
Antibacterial effect of silver nanoparticles in Pseudomonas aeruginosa
R. Salomoni et al.
NANOTECHNOLOGY SCIENCE AND APPLICATIONS (2017)
Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature
B. Grabein et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)
Sibylle H. Lob et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
Andre C. Kalil et al.
CLINICAL INFECTIOUS DISEASES (2016)
A two-centre evaluation of RAPIDEC® CARBA NP for carbapenemase detection in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp.
Muhammad Humaun Kabir et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
Tripartite assembly of RND multidrug efflux pumps
Laetitia Daury et al.
NATURE COMMUNICATIONS (2016)
β-Lactams and β-Lactamase Inhibitors: An Overview
Karen Bush et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Antimicrobial agents targeting bacterial cell walls and cell membranes
K. BUSH
REVUE SCIENTIFIQUE ET TECHNIQUE-OFFICE INTERNATIONAL DES EPIZOOTIES (2016)
Ceftolozane-tazobactam: A new-generation cephalosporin
David Cluck et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2015)
Role of Pseudomonas aeruginosa Low-Molecular-Mass Penicillin-Binding Proteins in AmpC Expression, β-Lactam Resistance, and Peptidoglycan Structure
Alaa Ropy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
M. Berrazeg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The increasing threat of Pseudomonas aeruginosa high-risk clones
Antonio Oliver et al.
DRUG RESISTANCE UPDATES (2015)
Association of overexpression of efflux pump genes with antibiotic resistance in Pseudomonas aeruginosa strains clinically isolated from urinary tract infection patients
Katsumi Shigemura et al.
JOURNAL OF ANTIBIOTICS (2015)
The absence of the Pseudomonas aeruginosa OprF protein leads to increased biofilm formation through variation in c-di-GMP level
Emeline Bouffartigues et al.
FRONTIERS IN MICROBIOLOGY (2015)
Alarming and increasing prevalence of multidrug-resistant Pseudomonas aeruginosa among healthcare-associated infections in China: A meta-analysis of cross-sectional studies
Yang Peng et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2015)
What It Takes to Be a Pseudomonas aeruginosa? The Core Genome of the Opportunistic Pathogen Updated
Benoit Valot et al.
PLOS ONE (2015)
Transcriptional Analysis of MexAB-OprM Efflux Pumps System of Pseudomonas aeruginosa and Its Role in Carbapenem Resistance in a Tertiary Referral Hospital in India
Debarati Choudhury et al.
PLOS ONE (2015)
The Pseudomonas aeruginosa CreBC Two-Component System Plays a Major Role in the Response to β-Lactams, Fitness, Biofilm Growth, and Global Regulation
Laura Zamorano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitations
Jingjing Sun et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Ceftolozane/Tazobactam: A Novel Cephalosporin/beta-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2014)
Investigation of plasmid-mediated quinolone resistance in Pseudomonas aeruginosa clinical isolates
Y. Tanriverdi Cayci et al.
INDIAN JOURNAL OF MEDICAL MICROBIOLOGY (2014)
OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China
Zhi-li Fang et al.
INFECTION GENETICS AND EVOLUTION (2014)
Characterization of a novel Zn2+-dependent intrinsic imipenemase from Pseudomonas aeruginosa
Alicia Fajardo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Outbreak of PER-1 and diversity of β-lactamases among ceftazidime-resistant Pseudomonas aeruginosa clinical isolates
Yun Qing et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2014)
Prevalence of Extended-Spectrum and Metallo β-Lactamase Production in AmpC β-Lactamase Producing Pseudomonas aeruginosa Isolates From Burns
Roya Rafiee et al.
JUNDISHAPUR JOURNAL OF MICROBIOLOGY (2014)
A new strategy to fight antimicrobial resistance: the revival of old antibiotics
Nadim Cassir et al.
FRONTIERS IN MICROBIOLOGY (2014)
Acquired Class D β-Lactamases
Nuno T. Antunes et al.
ANTIBIOTICS-BASEL (2014)
Metallo-beta-lactamase structure and function
Timothy Palzkill
ANTIMICROBIAL THERAPEUTICS REVIEWS: THE BACTERIAL CELL WALL AS AN ANTIMICROBIAL TARGET (2013)
Structural Analysis of the Role of Pseudomonas aeruginosa Penicillin-Binding Protein 5 in β-Lactam Resistance
Jeffrey D. Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pseudomonas in augmented care: should we worry?
Michael Kelsey
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Study on drug resistance of Pseudomonas aeruginosa plasmid-mediated AmpC β-lactamase
Bin Zhu et al.
MOLECULAR MEDICINE REPORTS (2013)
Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Detection of P. aeruginosa harboring blaCTX-M-2, blaGES-1 and blaGES-5, blaIMP-1 and blaSPM-1 causing infections in Brazilian tertiary-care hospital
Milena Polotto et al.
BMC INFECTIOUS DISEASES (2012)
Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies
Hui Li et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2012)
From the regulation of peptidoglycan synthesis to bacterial growth and morphology
Athanasios Typas et al.
NATURE REVIEWS MICROBIOLOGY (2012)
Molecular Epidemiology of a Pseudomonas aeruginosa Hospital Outbreak Driven by a Contaminated Disinfectant-Soap Dispenser
Simone Lanini et al.
PLOS ONE (2011)
Pseudomonas aeruginosa: all roads lead to resistance
Elena B. M. Breidenstein et al.
TRENDS IN MICROBIOLOGY (2011)
Pseudomonas aeruginosa: resistance to the max
Keith Poole
FRONTIERS IN MICROBIOLOGY (2011)
Nosocomial Pneumonia in the Intensive Care Unit Acquired by Mechanically Ventilated versus Nonventilated Patients
Mariano Esperatti et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Diversity, Epidemiology, and Genetics of Class D beta-Lactamases
Laurent Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues
V. Miriagou et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
How antibiotics kill bacteria: from targets to networks
Michael A. Kohanski et al.
NATURE REVIEWS MICROBIOLOGY (2010)
Efflux Unbalance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients
Lucie Vettoretti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa
Jose-Manuel Rodriguez-Martinez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
Philip D. Lister et al.
CLINICAL MICROBIOLOGY REVIEWS (2009)
Efflux-Mediated Drug Resistance in Bacteria An Update
Xian-Zhi Li et al.
DRUGS (2009)
The Glycerol-3-Phosphate Permease GlpT Is the Only Fosfomycin Transporter in Pseudomonas aeruginosa
Alfredo Castaneda-Garcia et al.
JOURNAL OF BACTERIOLOGY (2009)
Mechanistic Basis for the Emergence of Catalytic Competence against Carbapenem Antibiotics by the GES Family of β-Lactamases
Hilary Frase et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Sensitive Screening Tests for Suspected Class A Carbapenemase Production in Species of Enterobacteriaceae
Fernando Pasteran et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
β-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein
Bartolome Moya et al.
PLOS PATHOGENS (2009)
The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis
Eric Sauvage et al.
FEMS MICROBIOLOGY REVIEWS (2008)
Carbapenemases:: the versatile β-lactamases
Anne Marie Queenan et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumonide in Brooklyn, NY
David Landman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase
Maria Virginia Villegas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Multidrug-resistance efflux pumps - not just for resistance
Laura J. V. Piddock
NATURE REVIEWS MICROBIOLOGY (2006)
Class II transposon-borne structure harboring metallo-β-lactamase gene blaVIM-2 in Pseudomonas putida
Laurent Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Pseudomonas aeruginosa porin OprF exists in two different conformations
Etsuko Sugawara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
BEL-1, a novel clavulanic acid-inhibited extended-spectrum β-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa
L Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Is it necessary to change the classification of β-lactamases?
JM Frère et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Metallo-β-lactamases:: the quiet before the storm?
TR Walsh et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia
M Paul et al.
LANCET INFECTIOUS DISEASES (2005)
Phosphonoformate: A minimal transition state analogue inhibitor of the fosfomycin resistance protein, FosA
RE Rigsby et al.
BIOCHEMISTRY (2004)
Integrons and β-lactamases -: a novel perspective on resistance
GF Weldhagen
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2004)
Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa
D Girlich et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps:: the large periplasmic loops of MexD from Pseudomonas aeruginosa are involved in substrate recognition
WM Mao et al.
MOLECULAR MICROBIOLOGY (2002)
Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD
N Bagge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa
DS Burgess et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2002)
Critical involvement of a carbamylated lysine in catalytic function of class D β-lactamases
D Golemi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Antibiotic resistance of bacteria in biofilms
PS Stewart et al.
LANCET (2001)
Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics:: Penem resistance mechanisms and their interplay
K Okamoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa
D Aubert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
CK Stover et al.
NATURE (2000)